IDiyas

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Charles M Blazey

USPTO Granted Patents = 15 

 

 

Average Co-Inventor Count = 13.3

ph-index = 4

Forward Citations = 64(Granted Patents)


Company Filing History:

goldMedal11 out of 173 
 
Exelixis, Inc.
 patents
silverMedal4 out of 10 
 
Symphony Evolution, Inc.
 patents

Years Active: 2010-2023

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 11597699 - MEK inhibitors and methods of their use (2023-03-07),
2. 10266518 - Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof (2019-04-23),
3. 9796704 - Substituted quinazolines as receptor-type kinase inhibitors (2017-10-24),
4. 9359332 - Processes for the preparation of substituted quinazolines (2016-06-07),
5. 8697737 - Raf modulators and methods of use (2014-04-15),
6. 8658654 - Receptor-type kinase modulators and methods of use (2014-02-25),
7. 8648066 - Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture (2014-02-11),
8. 8362002 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2013-01-29),
9. 8101625 - Pyrimidinones as Casein Kinase II (CK2) modulators (2012-01-24),
10. 8076338 - Kinase modulators and methods of use (2011-12-13),
11. 8012956 - Tropane compounds (2011-09-06),
12. 7915250 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2011-03-29),
13. 7872014 - Anaplastic lymphoma kinase modulators and methods of use (2011-01-18),
14. 7846959 - Raf modulators and methods of use (2010-12-07),
15. 7803839 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2010-09-28),

Title: The Innovative Contributions of Charles M Blazey

Introduction

Charles M Blazey is a prominent inventor based in San Francisco, CA, known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, Blazey has made remarkable advancements, particularly in the treatment of proliferative diseases such as cancer. His work has had a profound impact on the development of new therapeutic strategies.

Latest Patents

Blazey's latest patents include groundbreaking inventions such as MEK inhibitors and methods of their use. These compounds, which are useful in treating proliferative diseases, particularly cancer, are disclosed in his patent. The invention includes pharmaceutical compositions containing these compounds and methods for their application in cancer treatment. Another notable patent involves solid dosage formulations of substituted quinazoline receptor-type kinase modulators. This invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and addresses diseases characterized by abnormal levels of cell proliferation, apoptosis, cell migration, and angiogenesis associated with tumor growth.

Career Highlights

Throughout his career, Charles M Blazey has worked with several notable companies, including Exelixis, Inc. and Symphony Evolution, Inc. His experience in these organizations has allowed him to refine his expertise and contribute to significant advancements in pharmaceutical research and development.

Collaborations

Blazey has collaborated with esteemed colleagues such as Neel Kumar Anand and Joerg Bussenius. These partnerships have further enhanced his innovative work and have played a crucial role in the success of his projects.

Conclusion

Charles M Blazey's contributions to the field of pharmaceuticals through his patents and collaborations have made a lasting impact on the treatment of cancer and other proliferative diseases. His innovative spirit continues to inspire advancements in medical research and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…